Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial.
Summary
In a double-blind phase 3 trial (n=337) of EGFR-mutant NSCLC, limertinib significantly prolonged ICR-assessed PFS versus gefitinib (20.7 vs 9.7 months; HR 0.44), with comparable rates of grade ≥3 adverse events (25% each). Serious treatment-related events were fewer with limertinib, supporting it as a first-line option.
Key Findings
- Median PFS 20.7 vs 9.7 months (HR 0.44; p<0.0001) favoring limertinib
- Grade ≥3 treatment-related adverse events occurred in 25% in both arms
- Serious treatment-related AEs were 5% with limertinib vs 10% with gefitinib; three treatment-related deaths occurred only in the gefitinib arm
Clinical Implications
Limertinib should be considered a first-line EGFR TKI in sensitizing EGFR mutations, particularly where gefitinib remains in use; head‑to‑head data suggest improved disease control without added toxicity.
Why It Matters
This rigorous phase 3 RCT demonstrates clear efficacy superiority of a third‑generation EGFR TKI against a standard comparator, likely informing first‑line standards in EGFR‑mutant NSCLC.
Limitations
- Conducted entirely in China; generalizability across ancestries and care settings requires confirmation
- Comparator was gefitinib rather than osimertinib; overall survival not yet mature
Future Directions
Head-to-head trials versus osimertinib, biomarker-defined subgroup analyses (e.g., CNS disease), resistance mechanisms to limertinib, and OS readouts are needed.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Randomized, double-blind phase 3 trial provides highest level of clinical evidence
- Study Design
- OTHER